| Pranay Kathuria, MD FACP | |
|
591 E 36th St N, Tulsa, OK 74106-1812 | |
| (918) 619-4400 | |
| (918) 619-4591 |
| Full Name | Pranay Kathuria |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 42 Years |
| Location | 591 E 36th St N, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073583431 | NPI | - | NPPES |
| 100257970C | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 20384 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Fmcna - Xanthus Dialysis | Tulsa, OK | Dialysis facility |
| Fmcna - Sapulpa Dialysis | Sapulpa, OK | Dialysis facility |
| Fmcna - Bailey Dialysis Center | Owasso, OK | Dialysis facility |
| Davita - Central Tulsa | Tulsa, OK | Dialysis facility |
| St John Medical Center, Inc | Tulsa, OK | Hospital |
| Hillcrest Medical Center | Tulsa, OK | Hospital |
| Ascension St John Broken Arrow | Broken arrow, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Board Of Regents Of The University Of Oklahoma Ou Physicians Tulsa | 5395645329 | 89 |
News Archive
A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.
A tuberculosis vaccine administered during the past 15 years is associated with significantly improved COVID-19 outcomes, according to a new study published in Vaccines.
A drug that removes excess iron and toxins from the body after a brain bleed did not show significant improvement in recovery or neurological function at three months after intracerebral hemorrhage (stroke), but showed some benefits at six months, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).
› Verified 6 days ago
| Entity Name | Ctca Physicans Group Of Oklahoma, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053309591 PECOS PAC ID: 2163328774 Enrollment ID: O20031212000074 |
News Archive
A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.
A tuberculosis vaccine administered during the past 15 years is associated with significantly improved COVID-19 outcomes, according to a new study published in Vaccines.
A drug that removes excess iron and toxins from the body after a brain bleed did not show significant improvement in recovery or neurological function at three months after intracerebral hemorrhage (stroke), but showed some benefits at six months, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).
› Verified 6 days ago
| Entity Name | Board Of Regents Of The University Of Oklahoma Ou Physicians Tulsa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154385730 PECOS PAC ID: 5395645329 Enrollment ID: O20040113000654 |
News Archive
A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.
A tuberculosis vaccine administered during the past 15 years is associated with significantly improved COVID-19 outcomes, according to a new study published in Vaccines.
A drug that removes excess iron and toxins from the body after a brain bleed did not show significant improvement in recovery or neurological function at three months after intracerebral hemorrhage (stroke), but showed some benefits at six months, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Pranay Kathuria, MD FACP Po Box 268838, Oklahoma City, OK 73126-8838 Ph: (918) 619-4400 | Pranay Kathuria, MD FACP 591 E 36th St N, Tulsa, OK 74106-1812 Ph: (918) 619-4400 |
News Archive
A research team today reported clinical results of a new method for analyzing the molecular activity of cancer drugs for solid tumors using skin biopsies. The approach, enabled by Cambridge Research & Instrumentation, Inc.'s imaging and analysis systems, was presented in a poster session at the American Association of Cancer Research's Annual Meeting in Washington D.C.
A tuberculosis vaccine administered during the past 15 years is associated with significantly improved COVID-19 outcomes, according to a new study published in Vaccines.
A drug that removes excess iron and toxins from the body after a brain bleed did not show significant improvement in recovery or neurological function at three months after intracerebral hemorrhage (stroke), but showed some benefits at six months, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.
For the third year in a row, the American Society of Clinical Oncology (ASCO) has included Erbitux® (cetuximab) research in its annual report, Clinical Cancer Advances, which features the most significant studies of 2010. The report cites as a notable advance this year the finding that BRAF mutation status is a prognostic, not predictive, marker for Erbitux efficacy in metastatic colorectal cancer (mCRC).
› Verified 6 days ago
Sarah Anne Shaw-dressler, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave Ste 100a, Tulsa, OK 74136 Phone: 918-494-8500 Fax: 918-307-5578 | |
Julia Margaret Kwon, DO Nephrology Medicare: Medicare Enrolled Practice Location: 1705 E 19th St Ste 302, Tulsa, OK 74104 Phone: 918-748-7585 Fax: 918-748-7539 | |
Peter Madden, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4502 E 41st St, Tulsa, OK 74135 Phone: 918-619-4400 | |
Thao Tran, D.O Nephrology Medicare: Accepting Medicare Assignments Practice Location: 4502 E. 41st Street, Tulsa, OK 74135 Phone: 918-619-4400 | |
Robert Peter Aran, D.O. Nephrology Medicare: Medicare Enrolled Practice Location: 6160 S Yale Ave Ste 100, Tulsa, OK 74136 Phone: 918-497-3300 Fax: 918-497-3365 | |
Robert Dean Okada, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave, Ste 304, Tulsa, OK 74136 Phone: 918-494-5300 Fax: 918-494-5455 | |
Dr. Charles Wade Taylor, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 12697 E 51st St, Tulsa, OK 74146 Phone: 918-505-3200 Fax: 918-505-3253 |